Clinical trial
Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment
NCT06550128 is registered in ClinicalTrials.gov with Ausper Biopharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment
- Lead sponsor
- Ausper Biopharma Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 10, 2024
- Completion date
- January 26, 2026
- Enrollment
- 86 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.